SOUTH SAN FRANCISCO, California, Oct. 22 (TNSxrep) -- Genentech, a member of the Roche Group, issued the following news release:

* * *

Genentech Presents New Pivotal Trial Data Across Broad Neuroimmunology Portfolio at MSToronto2026

* Fenebrutinib FENtrepid and FENhance 1 & 2 late-breaking data demonstrate a therapeutic effect on chronic active lesions, addressing a primary driver of long-term disability progression in multiple sclerosis (MS)

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:

What's your Affiliation

Government Newspaper / Media Business Public Policy Individual / Student Educators

Email:

Phone:

Organization, if any:

State/Country you are in:

Additional questions or comments:

Submit Form Click here for more information about our products